Lansoprazol Farmoz

Lansoprazole, the active ingredient in Lansoprazol Farmoz, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production in adults with acid‑related gastrointestinal conditions.

GNH USA supplies Lansoprazol Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage disorders associated with excess gastric acid.

Gastroesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. Peptic ulcer disease: accelerates ulcer healing and reduces recurrence risk. Helicobacter pylori eradication therapy: enhances bacterial clearance when combined with antibiotics. Erosive esophagitis: facilitates mucosal recovery and prevents further damage.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea: occasional, may improve with food. - Abdominal pain: dull discomfort. - Flatulence: increased gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Severe allergic reactions: rash, swelling, anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: monitor liver function. - Hypomagnesemia: prolonged use may lower magnesium levels. - Interstitial nephritis: rare kidney inflammation.

Before prescribing Lansoprazole, consider the following safety measures. - Assess renal function: adjust use in severe impairment. - Review concomitant medications: avoid reduced efficacy of clopidogrel. - Limit duration: long‑term therapy may increase fracture risk. - Pregnancy considerations: limited data, use only if benefit outweighs risk. - Store at room temperature: keep in the original pack, protect from moisture.

Lansoprazole may affect the pharmacokinetics of several drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - High‑dose methotrexate: increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may raise serum levels. - Diazepam: potential elevation of drug concentration.